Investor directory

Chiesi Ventures

Chiesi Ventures is a venture capital firm that invests in early stage opportunities operating in the area of rare and orphan disorders. The company funds research and development opportunities for therapies of rare diseases and aims to improve the quality of diagnosis, disease management, care and therapy to all patients affected by rare diseases. It also aims to accelerate the expansion of the Chiesi network in the U.S. among universities, venture capital investors, rare disease patient organizations, and entrepreneurial companies developing treatments for rare diseases. On September 2, 2014, Chiesi Ventures and A. M. Pappas & Associates announced a strategic collaboration. Chiesi Ventures was founded on September 2, 2014, and is headquartered in Parma, Italy with presence in the United States. It is owned by Chiesi Group.

Focus

TherapeuticsSeries BScale StageNanotechnologyPharmaceuticalsShow more
http://www.chiesiventures.com
https://crunchbase.com/organization/chiesi-ventures
https://www.capitaliq.com/CIQDotNet/company.aspx?companyId=271523906

Giacomo Chiesi

Managing Partner

22 past transactions

CuraSen Therapeutics

Series A in 2018
Curasen Therapeutics Inc. operates as a biotechnology company which develops therapies to treat neurodegenerative diseases. It also develops small molecule drugs that targets a novel mechanism in the brain to restore function, improve symptoms, and modify diseases, such as less common (orphan) neurodegenerative disorders, and Parkinson's disease and Alzheimer's disease. The company was incorporated in 2016 and is based in Los Altos, California.

Glycomine

Series B in 2019
Glycomine, Inc. develops nanomedicines for rare genetic disorders. It focuses on genetic disorders of protein and lipid glycosylation, which often cause severe debilitation in patients. The company was incorporated in 2014 and is based in San Carlos, California.

Glycomine

Series B in 2021
Glycomine, Inc. develops nanomedicines for rare genetic disorders. It focuses on genetic disorders of protein and lipid glycosylation, which often cause severe debilitation in patients. The company was incorporated in 2014 and is based in San Carlos, California.

Sentieon

Series A in 2017
Sentieon develops and commercializes cloud-based bio-informatics solutions for the life sciences and clinical market. They develop and supply a suite of bioinformatics secondary analysis tools that process genomics data with high computing efficiency, fast turnaround time, accuracy, and consistency. Some of the released products include Sentieon DNAseq, a germline DNA pipeline; and Sentieon TNseq, for tumor-normal somatic variant detection. The company’s tools are scalable, deployable, upgradable, and software-only solutions. The Sentieon tools achieve their efficiency and consistency through optimized computing algorithm design and enterprise-strength software implementation. The company was founded by Jun Ye in 2014 and is headquartered in Mountain View, California.

Minoryx

Series B in 2018
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Aura Biosciences

Venture Round in 2021
Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

VelosBio

Private Placement in 2018
VelosBio, Inc., a biopharmaceutical company, develops novel antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company develops cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). Its portfolio includes VLS-101, a ROR1-directed antibody-drug conjugate for patients with hematologic and solid tumor malignancies. The company was incorporated in 2017 and is headquartered in San Diego, California. As of December 18, 2020, VelosBio, Inc. operates as a subsidiary of Merck & Co., Inc.

Kezar Life Sciences

Series B in 2017
Kezar Life Sciences company focused on the discovery and development of drugs targeting protein homeostasis for autoimmune disorders. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential.

Reneo Pharmaceuticals

Series B in 2020
Reneo Pharmaceuticals is an operator of a pharmaceutical company used to develop therapies for patients with orphan metabolic diseases. It focuses on the development of treatments for genetic disorders associated with defects in energy metabolism resulting in myopathy that enable caregivers to improve the daily function and quality of life of patients suffering from these diseases by improving how their mitochondria work, preserving muscle function and preventing muscle injury, weakness, and wasting. The company was founded in 2014 and is headquartered in San Diego, California.

Minoryx

Private Placement in 2018
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

4D Molecular Therapeutics

Private Placement in 2020
4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

VelosBio

Series A in 2018
VelosBio, Inc., a biopharmaceutical company, develops novel antibody-drug conjugates (ADCs) to treat hematological cancers and solid tumors. The company develops cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). Its portfolio includes VLS-101, a ROR1-directed antibody-drug conjugate for patients with hematologic and solid tumor malignancies. The company was incorporated in 2017 and is headquartered in San Diego, California. As of December 18, 2020, VelosBio, Inc. operates as a subsidiary of Merck & Co., Inc.

4D Molecular Therapeutics

Private Placement in 2018
4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Mirum Pharmaceuticals

Series A in 2018
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Aura Biosciences

Series C in 2017
Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

4D Molecular Therapeutics

Series B in 2018
4D Molecular Therapeutics is a biotechnology company.The Company designs, develops, and commercializes transformative gene therapeutic products for unmet medical conditions.

Aura Biosciences

Private Placement in 2019
Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

Glycomine

Series A in 2016
Glycomine, Inc. develops nanomedicines for rare genetic disorders. It focuses on genetic disorders of protein and lipid glycosylation, which often cause severe debilitation in patients. The company was incorporated in 2014 and is based in San Carlos, California.

Minoryx

Series A in 2015
Minoryx, they are committed to finding innovative treatments for life threatening rare diseases. They focus on pediatric diseases and they are currently working on treatments for neurometabolic diseases of genetic origin.Minoryx develops a new generation of small molecule drugs known as pharmacological chaperones, which offer the most promising approach to the treatment of genetic diseases severely affecting the central nervous system. As a complementary approach, Minoryx is also involved in repositioning-based projects.

Aura Biosciences

Series B in 2015
Aura Biosciences, Inc., a biotechnology company, develops a class of therapies to target and destroy cancer cells using viral nano-particle conjugates. The company develops AU-011 that includes viral nanoparticles, modeled on the human papillomavirus (HPV), conjugated to infrared-activated small molecules. The company’s AU-011 is used for the treatment of ocular (uveal) melanoma, which is a primary cancer of the eye. The company was incorporated in 2009 and is based in Cambridge, Massachusetts.

Glycomine

Private Placement in 2019
Glycomine, Inc. develops nanomedicines for rare genetic disorders. It focuses on genetic disorders of protein and lipid glycosylation, which often cause severe debilitation in patients. The company was incorporated in 2014 and is based in San Carlos, California.

Sentien Biotechnologies

Series A in 2017
Sentien Biotechnologies, Inc. develops proprietary cell compositions and GMP manufacturing methods to advance combination products that unlock the potential of cell therapy. It provides the Sentinel, a device that actively treats patients during a dialysis dose by supplementing patient blood with MSC-derived secretions, a combinational mixture of natural anti-inflammatory and trophic molecules that can attenuate the immune dysfunction of acute renal failure while promoting a tissue repairing response. The company was founded in 2008 and is headquartered in Medford, Massachusetts.